Breast Cancer (AKT Pathway Gene Testing) [Tissue]

Three mock clinical cases with matching human tumour tissue paraffin embedded (FFPE) and/or artificial FFPE (designed to simulate real patient samples). One 10um or 15um FFPE section per case is provided.

Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials. Variant allele frequencies of any artificial FFPE reference materials have been validated using ddPCR. 

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

The minimum requirement is PIK3CA gene testing. If you provide a clinical service for the AKT1 and PTEN genes, these should be included.

These samples are not suitable for an RNA-based methodology only.

Participants are expected to test the samples according to their routine strategy. For all cases, participants are expected to return a clinical report and complete an online data collection form. 

This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. EMQN would like to acknowledge and thank AstraZeneca for this support. 

Restricted to 150 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc)